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Abstract
Background: Endothelial differentiation occurs during normal vascular development in the
developing embryo. This process is recapitulated in the adult when endothelial progenitor cells are
generated in the bone marrow and can contribute to vascular repair or angiogenesis at sites of
vascular injury or ischemia. The molecular mechanisms of endothelial differentiation remain
incompletely understood. Novel approaches are needed to identify the factors that regulate
endothelial differentiation.
Methods: Mouse embryonic stem (ES) cells were used to further define the molecular
mechanisms of endothelial differentiation. By flow cytometry a population of VEGF-R2 positive cells
was identified as early as 2.5 days after differentiation of ES cells, and a subset of VEGF-R2+ cells,
that were CD41 positive at 3.5 days. A separate population of VEGF-R2+ stem cells expressing the
endothelial-specific marker CD144 (VE-cadherin) was also identified at this same time point.
Channels lined by VE-cadherin positive cells developed within the embryoid bodies (EBs) formed
by differentiating ES cells. VE-cadherin and CD41 expressing cells differentiate in close proximity
to each other within the EBs, supporting the concept of a common origin for cells of hematopoietic
and endothelial lineages.
Results: Microarray analysis of >45,000 transcripts was performed on RNA obtained from cells
expressing VEGF-R2+, CD41+, and CD144+ and VEGF-R2-, CD41-, and CD144-. All microarray
experiments were performed in duplicate using RNA obtained from independent experiments, for
each subset of cells. Expression profiling confirmed the role of several genes involved in
hematopoiesis, and identified several putative genes involved in endothelial differentiation.
Conclusion: The isolation of CD144+ cells during ES cell differentiation from embryoid bodies
provides an excellent model system and method for identifying genes that are expressed during
endothelial differentiation and that are distinct from hematopoiesis.
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Background
A close temporal and spatial association exists between
the development of hematopoietic and endothelial stem
cells during embryogenesis. This is first observed in extraembryonic mesodermal tissues such as the yolk sac.
Within the developing yolk sac primitive erythrocytes are
surrounded by a layer of angioblasts [1,2]. The close temporal and spatial association of these two lineages led to
the hypothesis that they arise from a common precursor
of mesodermal origin known as the hemangioblast [3].
Further support for the existence of a common precursor
comes from gene targeting disruption studies, which demonstrate that some genes are essential for the development
of both lineages. For example, the SCL/tal-1 gene, previously described for its essential role during hematopoiesis, is also expressed in the developing vasculature and is
required for vascular remodeling during embryogenesis
[4,5]. One of the earliest cell surface markers that defines
this bipotential cell is the VEGF receptor-2 (VEGF-R2).
Targeted disruption of VEGF-R2 similarly leads to defects
in vasculogenesis and hematopoiesis [6].
One powerful tool to study the earliest steps in the differentiation of hematopoietic and endothelial cells is the use
of embryonic stem cells in culture [7]. Most studies suggest that the molecular events leading to the development
of the hematopoietic and endothelial lineages in embryoid bodies (EBs) derived from ES cells in culture are very
similar to those observed during embryonic development
[8,9]. During ES cell differentiation, blast colony-forming
cells (BL-CFCs) can be isolated from EBs that exhibit
endothelial and hematopoietic potential [8]. BL-CFCs
expressing VEGF-R2 can be identified within EBs about
2.5 days.
Several transcription factors that are required for definitive hematopoiesis have been identified (Table 2). The
transcription factor Runx1 (AML1), a member of the core
binding factor (CBF) family of transcription factors is
required for the establishment of definitive, but not primitive hematopoiesis [10]. The transcription factor GATA-1
is required for differentiation of the erythroid lineage
[11]. Finally, the homeobox transcription factor HoxB4
was shown to promote the potential of hematopoietic
stem cells derived from ES cells that contribute to definitive hematopoiesis, promoting the development of selfrenewing, long term, hematopoietic progenitors [12].
Considerably less is known about the transcription factors
and the molecular mechanisms that regulate endothelial
differentiation. The purpose of this study was to use an ES
cell differentiation system to identify genes that are preferentially expressed at early and later stages of endothelial
differentiation. We identified four populations of cells;
cells expressing VEGF-R2 (day 2.5), CD41 expressing cells
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(day 3.5), cells expressing CD144 (VE-cadherin, day 3.5),
and cells expressing CD144 (day 6.5). As negative control
we have also isolated VEGF-R2 negative (day 2.5), CD41
negative (day 3.5), negative CD144 (VE-Cadherin, day
3.5), and negative CD144 (day 6.5). In addition, we isolated CD144 positive and CD144 negative cells from
mouse embryos at embryonic day 9.5. Microarray analysis
of the RNA isolated from each of these populations of
cells allowed for the identification of genes expressed in
these subsets of cells and suggest their potential role during the differentiation of embryonic stem cells along the
endothelial lineage.

Methods
ES cell culture
CCE Embryonic stem cells (ATCC) were maintained on
irradiated primary embryonic fibroblasts (Chemicon) in
knockout DMEM (Invitrogen/Gibco-BRL) supplemented
with 15% fetal bovine serum (Hyclone, Logan, UT), penicillin/streptomycin 1% (Invitrogen/Gibco-BRL), lglutamine 2 mM (Invitrogen/Gibco-BRL), non-essential
amino acids 0.1 mM, nucleosides 0.1 mM, 2-mercaptoethanol 0.1 mM (Sigma, St. Louis, MO), monothioglycerol (MTG) 2 mM (Sigma), and ESGRO leukemia
inhibitory factor (LIF) 1000 units/ml (Sigma). ES cells
were grown in LIF-containing media for 48 hours. To generate EBs, ES cells were separated from the feeder cells, replated at a density of 2 × 106 cells per 10 cm dish (Fisher
Scientific), and grown in media without LIF to promote
differentiation.
Flow Cytometry and Cell Sorting
To prepare single-cell suspensions EBs were washed with
PBS and disrupted by pipetting after 20 min treatment
with cell dissociation solution at 37°C (Sigma). Whole
embryo cells were dissected from the decidual tissue of
E9.5 pregnant 129/Sv mice and washed in PBS (Invitrogen). Dissected embryos were incubated for 60–90 minutes at 37°C in 0.1% collagenase/dispase (Sigma) and
20% fetal bovine serum (FBS, Hyclone) and subsequently
dissociated into a single-cell suspension. All cells were
fixed in 3:1 ethanol:glacial acetic acid and washed extensively in PBS prior to immunofluorescent staining. Cells
were initially incubated with rat-monoclonal anti-VE-cadherin antibody (1:100, Pharmingen, San Diego, CA) at
room temperature for 30 min, followed by labeling with
anti-rat fluorescein-isothiocynate (FITC)-conjugated antibody (1:100, Jackson Laboratories). Subsequent double
labeling with phycoerythrin (PE)-conjugated anti-VEGFR2 and -CD41 antibodies (1:100, Pharmingen) was also
performed at room temperature for 30 min. Flow cytometry and cell sorting was completed on the FC5000 Flow
Cytometer at the Beth Israel Deaconess Medical Center
Flow Cytometry Core Facility using CXP Analysis Program.
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RNA Extraction and Quantitative RT-PCR
Total RNA from FACS-sorted cells was isolated using an
RNeasy kit (Qiagen). Real-time PCR was performed containing SYBR green I (1:1000 dilution, Molecular Probes),
forward and reverse primers (0.8 μM each), 0.8 mM
dNTPs, 2 mM MgCl2, 1U Taq Polymerase (Promega), and
1U Platinum Taq Antibody (Invitrogen) in 1xPCR Buffer
under the following conditions: denaturation at 95°C (3
min); 35 cycles at 94°C (1 min), at 60°C (1 min), at 72°C
(1 min). GAPDH was used as an internal reference in each
reaction. Amplification was followed by melting curve
analysis using the program run at the step acquisition
mode to verify the presence of a single amplification product in DNA. Accumulation of PCR products was monitored and determined using the Opticon Monitor (MJ
Research). The threshold cycle (CT) was determined using
the Opticon analysis software. Oligonucleotide Primers
for Quantitative RT-PCR for each gene were:

Ikaros: Forward GCCCTATGACAGTGCCAACT, Reverse
CAGCTGGTACATGGAGCTGA
AML1: Forward TGTTGGGCATTTGACTTTGA, Reverse
TTACTACCGGAGGGTTGTGG
Hemoglobin Y: Forward AAGCTCCGAGCACACCCACT,
Reverse AAGCTCTGAGCACACCCACT
CD41: Forward AAGCTCTGAGCACACCCACT, Reverse
CTCAGCCCTTCACTCTGACC
Endothelin Receptor B: Forward CAGGAAGAAGAGCGGTATGC, Reverse CACACCTGTGTGGATTGCTC
Thrombospondin: Forward CCAAAGCCTGCAAGAAAGAC, Reverse CCTGCTTGTTGCAAACTTGA
Tie1: Forward CAGGCACAGCAGGTTGTAGA, Reverse
GTGCCACCATTTTGACACTG
Tie2: Forward AAGCATGCCCATCTGGTTAC, Reverse
GTAGGTAGTGGCCACCCAGA
EphrinA1:
Forward
CCCACATTACGAGGACGACT,
Reverse CCCAAGCTAAAAGGCCTCAA
Flt-1: Forward CCAAGGCCTCCATGAAGATA, Reverse
ATACTGTCAGGGGCTGGTTG
MEF2C: Forward ACGCCTGTCACCTAACATCC, Reverse
AGCTCTCAAACGCCACACTT
KLF2: Forward CCAAGAGCTCGCACCTAAAG, Reverse
GTGGCACTGAAAGGGTCTGT
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Microarray analysis
For transcriptional profiling, the mouse genome 430 2.0
Affymetrix GeneChip, containing more than 45,000 transcripts was used. RNA for the microarray experiments was
obtained in duplicates from two separately conducted
experiments using the murine ES cells. Microarray analysis was conducted via the Genomics Center at the Beth
Israel Deaconess Medical Center, according to previously
described protocols for total RNA extraction and purification, cDNA synthesis, in vitro transcription reaction for
production of biotin-labeled cRNA, hybridization of
cRNA with mouse genome 430 2.0 Affymetrix gene chips,
and scanning of image output files [13]. The quality of the
scanned array images was determined on the basis of
background values, percent present calls, scaling factors,
and 3'-5' ratio of β-actin and GAPDH using the BioConductor R packages [14].

Scanned array images were analyzed by dChip, as it is
more robust than MAS5.0 and RMA in signal calculation.
The raw probe level data was normalized using smoothing-spline invariant set method. The signal value for each
transcript was summarized using perfect-match-only
(PMO) based signal modeling algorithm described in
dChip. The PMO based modeling algorithm yields less
number of false positives as compared to the PMO-MM
model (MM meaning "mismatch-match"). In this way,
the signal value corresponds to the absolute level of
expression of a transcript [15]. These normalized and
modeled signal values for each transcript were used for
further high-level bioinformatics analysis. During the calculation of model based expression signal values, array
and probe outliers are interrogated and images spike are
treated as signal outliers. The outlier detection was carried
out using dChip outlier detection algorithm. A chip is
considered as an outlier if the probe, single or array outlier
percentage exceeds a default threshold of 5%.
When comparing two groups of samples to identify genes
enriched in a given phenotype, if 90% lower confidence
bound (LCB) of the fold change (FC) between the two
groups was above 2.0, the corresponding gene was considered to be differentially expressed [16]. LCB is a stringent
estimate of FC and has been shown to be the better ranking statistic [15]. It has been suggested that a criterion of
selecting genes that have a LCB above 2.0 most likely corresponds to genes with an "actual" fold change of at least
3 in gene expression [16,17].
The final list of positive, phenotype-specific, differentially
expressed genes was generated by removing all the genes
that were also differentially expressed in the negative control population during the same transition. For example,
the initial list of differentially expressed genes for VEGFR2+/CD41+ at day 3.5 as compared to VEGF-R2+ at day 2.5
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was corrected by removing the genes that are also differentially expressed in the negative control cells (VEGF-R2-/
CD41- at day 3.5 compared to VEGF-R2- at day 2.5). Further corrections in the identified differentially expressed
genes were made by comparing changes in the expression
in negative populations (e.g. CD144-) versus positive
populations (e.g. VEGF-R2+ at day 2.5) over time.
The raw MIAME compliant microarray data is available
online in the GEO repository at NCBI [18].
Western Blot Analysis
Whole cell lysates (50 μg) of cells were boiled in Laemmli
buffer and resolved on 10% SDS-PAGE acrylamide gel.
Proteins were transferred on Hybond-PVDF membranes
and immunoblotted using the ECL Western Blotting
Detection reagents (Amersham Biosciences, UK). Polyclonal antibodies against VE-cadherin, CD41, and alpha
actin were obtained from Pharmingen.
Immunohistochemistry and microscopy of embryoid bodies
and the yolk sac
EBs from different time points (day 6.5 to 10.5) were
washed with PBS and embedded in OCT freezing compound (Miles Scientific, Cambridge, ML) after fixation in
4% paraformaldehyde for 1 hour at 4°C and cryoprotection in 20% (wt/vol) sucrose overnight. Frozen sections
(8–10 μm thick) were mounted onto gelatin-coated glass
slides, air-dried overnight, permeabilized for 3 minutes
with 0.5% Triton X-100, and washed two times with PBS.
Slides were then processed for immunofluorescence
microscopy using FITC-conjugated CD41, PE-conjugated
VE-cadherin, and FITC-vWF rat antibodies (1:100,
Pharmingen). 129/sv mice were bred to generate day E8.5
embryos. The yolk sac was dissected from the embryo
proper and fixed in 4% paraformaldehyde, and frozen in
OCT. Immunohistochemistry was performed using 10
μm sections. Fluorescent images were obtained using a
Nikon Eclispse E800 microscope (Nikon, Tokyo, Japan)
equipped with a 40 X/0.75 numeric aperture objective
lens as well as a Zeiss AxioCam digital camera (Carl Zeiss
International, Heidelberg, Germany). Images were analyzed using Openlab imaging software version 3.0.4
(Improvision, Lexington, MA).

Results
The molecular mechanisms underlying endothelial differentiation from pluripotent stem cells remain incompletely understood. We have used a murine ES cell
differentiation system to identify the genes involved in the
process of endothelial differentiation. Cells were grown in
the presence of LIF, and allowed to differentiate into cystic
EBs in the absence of LIF. VEGF-R2 positive cells were first
detected in ES cells by flow cytometry 2.5 days after the
initiation of differentiation (Figure 1A). Approximately
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11% of the ES cells expressed VEGF-R2 at this time point.
One day later (day 3.5) 20–25% of the ES cells express
VEGF-R2. We identified a small subset (4.4%) of VEGF-R2
expressing cells (Figure 1A, middle left) that express the
endothelial-cell specific cell surface antigen CD144 (VEcadherin) at 3.5 days. One of the earliest cell surface markers of the hematopoietic lineage has recently been identified as CD41 (glycoprotein IIb), which is first detected in
differentiating ES cells at 3.5 days [19]. Approximately 5%
of cells express CD41 and VEGF-R2 at this time point (Figure 1A, bottom right). At day 6.5, CD41 and CD144 are
still expressed on a subset of VEGF-R2 positive cells (3.8
and 5.2%, respectively). However, the individual expression of CD41 and CD144 seems to diverge onto separate
cell populations, with only a small percentage (1.7%) of
CD144 positive cells showing CD41 co-expression (Figure
1B, lower right panel). Also, by day 6.5, the number of
VEGF-R2 expressing-cells is significantly decreased
(approximately 11% at day 6.5, compared to 20% at day
3.5) (Figure 1B).
VE-cadherin is expressed on the surface of endothelial
cells, during vascular development and in the adult cells
[20]. To verify the expression of these cell surface markers
at the protein level, western blot analysis was performed
at different time points during ES cell differentiation. No
expression of CD41 or CD144 was observed at 2.5 days
(Figure 1D). However, at day 3.5 there was a significant
increase in the expression of both CD144 and CD41.
Because of the close temporal and spatial relationship
between hematopoiesis and endothelial differentiation in
the developing embryo, we were also interested in evaluating the spatial relationship between the expression of
CD41 and CD144 in the EBs. We observed the formation
of small channels within the EBs lined by CD144 positive
cells in 6.5 day EBs (Figure 3A). CD41 expressing cells
(green) were observed in discrete sections of the EBs, and
appeared to be located within the lumen of the channels
formed by the CD144 positive cells (red). Nuclear staining with DAPI demonstrated that the areas where CD41
and CD144 are expressed represent distinct regions within
the EBs (Figure 3A). Co-localization of CD41 and CD144
positive cells further validated the close proximity of cells
expressing these two markers. To further validate the
endothelial cell specific nature of the CD144 positive
cells, the expression of the endothelial cell specific marker
von Willebrand's factor (vWF) was also evaluated. The
expression pattern of CD144 and vWF observed in the EBs
is nearly identical (Figure 3B). To extend these studies we
also evaluated the expression of CD144 and CD41 in the
developing yolk sac. We observed a close association
between the expression of CD144 and CD41 in the yolk
sac, with the lumen of blood vessels in the yolk sac lined
by CD144 positive cells, and CD41 positive cells within
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Figureand
CD41
1 CD144 during ES cell differentiation
CD41 and CD144 during ES cell differentiation. (A) Flow cytometric analysis of stem cell differentiation. CCE murine ES
cells differentiated into cystic embryoid bodies after removal of LIF (see methods). Flow cytometry was used to determine the
expression of VEGF-R2, CD144, and CD41. VEGF-R2 positve cells were first detected at 2.5 days after the removal of LIF and
represent approximately 11% of the cells. CD144 and CD41 are first detected at day 3.5. Both markers, CD144 and CD41,
represent a subset of VEGF-R2 positive cells (4.4 and 5.5%, respectively). Only a small percentage of CD144 positive cells
(1.7%) co-express CD41 at day 3.5 (bottom right panel). Isotype controls are shown in the upper right panel. (B) CD144 and
CD41-expressing cells remain a subset of VEGF-R2 positive cells (5.2 and 3.8%, respectively) at day 6.5, however, at this time
point, the two cell markers are expressed on different cell populations (lower right panel). (C) A schematic of ES cell differentiation demonstrating the populations of cells isolated for microarray analysis. VEGF-R2 is a marker of the hemangioblast (HB).
CD41 is one of the earliest markers for the hematopoietic progenitor (HP) cells and can be detected as early as day 3.5, concurrently with the endothelial-specific marker CD144 (VE-cadherin) expressed on the angioblast (AB) at day 3.5, and also on
differentiated endothelial cells (ET) at day 6.5. (D) Protein expression of CD144 (VE-cadherin) and CD41 in embryonic stem
cell differentiation. Isolated proteins from developing stem cells on days 2.5 to 8.5 were separated on a 10% SDS-PAGE. Western blot analysis was performed with antibodies directed against CD144, CD41, and β-actin.

the lumen (Figure 4). These studies confirm the close temporal and spatial association between the differentiation
of endothelial cells and hematopoietic cells from pluripotent stem cells in the developing embryo, and support the
ability of murine ES cells to recapitulate the steps associated with hematopoietic and endothelial differentiation,
using an in vitro differentiation model.

To begin to define the molecular mechanisms underlying
the differentiation of hematopoietic and endothelial cells
from a bipotent hemangioblast, we performed microarray
experiments using RNA derived from different subsets of
ES cells at different time points during the process of differentiation. The four positive populations isolated (Figure 1C), included VEGF-R2 positive population at day 2.5
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A
cells pre-sorting (day 2.5)
79.6%

20.4%

sorted cells VEGF-R2-

sorted cells VEGF-R2+
97.5%

99%

VEGF-R2

B

cells pre-sorting (day 3.5)
95.5%

4.5%

sorted cells CD41-

sorted cells CD41+
99%

98.5%

CD41

C

cells pre-sorting (day 6.5)
80.5%

PE -ve

19.5%

PE +ve

sorted cells CD14499.6%

PE -ve

PE +ve

sorted cells CD144+
92.4%

PE -ve

PE +ve

CD144
Figurecontrols
Purity
2
for FACS sorting
Purity controls for FACS sorting. Dot-plots in this figure show EB cells labeled with (A) VEGF-R2 antibody at day 2.5, (B)
CD41 at day 3.5, and (C) CD144 marker at day 6.5. The plots on the left show total cell populations labeled with the specific
cell marker before FACS sorting, while the plots in the middle and right are the purity controls demonstrating the negative and
positive cell populations, respectively, after FACS sorting.
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Figure 3 of CD41 and CD144 in embryoid bodies
Expression
Expression of CD41 and CD144 in embryoid bodies. Immunohistochemical analysis of CD41 and CD144 staining of frozen embryoid body sections (see methods for details). (A) Evaluation of CD41 (green) and CD144 (red) staining by immunofluorescence in embryoid body at day 6.5. Overlapping images of CD41 and CD144 demonstrate spatial proximity of CD41/
CD144 expression. DAPI nuclear staining (blue) outlines the general embryoid body morphology and organization. Bar represents 300 μm. (B) Immunofluorescence staining for vWF (green), VE-Cadherin (red), and DAPI (blue) in embryoid bodies at
day 10.5. Colocalization of the two endothelial-specific markers, vWF and CD144, is evident in the merged images. Bar represents 200 μm.

(also referred to as hemangioblast (HB)), CD41 positive
population at day 3.5 (also referred to as hematopoietic
precursor (HP)), CD144 positive population at day 3.5
(also referred to as the angioblast (AB)), and CD144 positive population at day 6.5 (also referred to as endothelial
cell (ET)). Additionally, as negative control cells, we have
also isolated four negative populations, VEGF-R2 negative
population at day 2.5 (NHB), CD41 negative population
at day 3.5 (NHP), CD144 negative population at day 3.5
(NAB), and CD144 negative population at day 6.5 (NET).
Microarray analysis was performed using Affymetrix
Mouse Genome 430 2.0 chips at the Beth Israel Deaconess
Medical Center Microarray facility. Dot plots in Figure 2
demonstrate the efficiency of the FACS sorting and purity
of each of the isolated cell populations.

Early VEGF-R2 positive ES cells express several
mesodermal markers
One of the earliest markers of the bipotent hemangioblast
is VEGF-R2. These cells are of mesodermal origin, and
have previously been shown to express mesodermal markers such as brachyury [3]. We examined the expression of
genes in the VEGF-R2 positive population of cells at day
2.5, compared to those at later stages of ES cell differentiation such as VEGFR2+/CD41+ and VEGFR2+/CD144+
(Table 1,2,3,4,5,6,7). In addition to brachyury, we identified several other genes, including the homeobox genes
lim1, Mixl1, even skipped, and goosecoid, all of which are
highly expressed in the embryonic mesoderm (Table 1).
These results support the idea that the VEGF-R2 positive
cells, isolated at day 2.5 are of mesodermal origin and
undergo differentiation in this model system.
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differentiation [21]. The first of these to occur is primitive
erythropoiesis. We identified transcription factors
upstream of erythropoiesis, including AML-1, GATA-1,
and erythroid Krueppel-like factor (KLF1), and genes predominantly associated with the erythroid lineage (Table
2). However, Ikaros and Helios, two zinc finger transcription factors known to regulate lymphopoiesis, were also
enriched in this CD41-positive population [22,23].
Helios expression is restricted to cells of T cell origin.
These results suggest that either these transcription factors
exhibit additional functions at earlier stages of hematopoiesis or that initiation of other hematopoietic lineages, in addition to the erythroid lineage, occurs during ES
cell differentiation.

Figure 4 of CD41 and CD144 in the yolk sac
Expression
Expression of CD41 and CD144 in the yolk sac. Immunostaining of CD144 and CD41 within the yolk sac of E8.5
embryos (see methods for details). Similar to the staining
pattern observed in the embryoid body, a close proximity of
CD144 (red) and CD41-positive cells (green) is also
observed in the yolk sac. Bar represents 100 μm; see methods for details of microscopy.
Markers of Hematopoiesis in the CD41 expressing ES cells
at day 3.5
We identified a small population of VEGF-R2 positive
cells expressing the early hematopoietic marker CD41 and
cells not expressing CD41 (negative control) at day 3.5.
Microarray analysis was performed on RNA derived from
these cells. VEGFR2+/CD41+ compared to the VEGF-R2
positive cells at day 2.5 have 565 differentially expressed
transcripts. Out of these 565 transcripts, all the transcripts
that were differentially expressed in the negative control
cells in the same transition (VEGF-R2-/CD41- cells at day
3.5 as compared to VEGF-R2- cells at day 2.5 or VEGF-R2/CD41- cells at day 3.5 as compared to VEGF-R2+ cells at
day 2.5) were filtered out. The final list of VEGFR2+/
CD41+ specific differentially expressed transcripts consists
of genes associated with hematopoiesis (Table 2). It has
also been suggested that in vitro ES cell differentiation systems closely recapitulates the events associated with
hematopoietic development in the yolk sac, including
primitive erythropoiesis, megakaryocyte, and mast cell

Markers of endothelial differentiation expressed in CD144
positive cells
To evaluate whether genes of the endothelial lineage are
expressed in early CD144 (VE-cadherin) positive cells during ES cell differentiation, we compared microarray data
of RNA isolated from CD144 positive cells at day 3.5 to
VEGF-R2 positive cells at day 2.5. To identify genes that
are uniformly upregulated in the CD144 positive cells, we
also performed microarray analysis of RNA samples from
the negative controls (i.e CD144 negative cells at day 3.5
to VEGF-R2 negative cells at day 2.5). The CD144 positive
cells at day 3.5 have 483 differentially expressed transcripts that are further corrected by removing the transcripts differentially expressed in the negative control cells
in the same transition (CD144- day 3.5 vs. VEGF-R2- day
2.5) or (CD144- day 3.5 vs. VEGF-R2+ day 2.5). This final
list has enrichment of selected endothelial-specific genes,
including Tie1 and the endothelin receptor B (Table 3). In
addition, several transcription factors were identified as
being enriched at this stage, including Krueppel-like factor
2 (KLF2), the SRY-box (Sox) 11, and the Forkhead box P1
transcription factor.

To examine the specific gene expression profile at later
stages of endothelial differentiation, we performed microarray analysis of CD144 positive and CD144 negative cells
isolated from ES cells 6.5 days after differentiation. The
CD144 positive cells at day 6.5 compared to VEGF-R2
positive cells obtained at day 2.5 showed differential
expression of 1068 transcripts. Transcripts that were dif-

Table 1: Mesodermal Markers Up-regulated in VEGF-R2 positive cells at day 2.5 of ES Cell Differentiation*

Gene Bank accession

Gene

HBvsHP

HBvsAB

AF154573
AV335209
NM_009309
NM_007966
NM_010351

Mix1 homeobox
Lim homeobox protein 1
Brachyury
Even skipped homeotic gene
Goosceoid

22.43
10.11
9.90
13.82
9.44

21.00
13.33
12.01
14.28
10.46
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Table 2: Comparison of CD41-postive (day 3.5) to VEGF-R2 positive cells (day 2.5)*

Gene Bank Accession number

Gene

Fold Change

M26898
AV311770
AV156860
NM_010369
AK010968
NM_013706
NM_010824
NM_053149
NM_010635
NM_008089
AV317621
BB319935
BB795285

Hemoglobin X
Hemoglobin Z
Hemoglobin Y
Glycophorin A
Erythropoietin receptor
CD52
Myeloperoxidase
Hemogen
Krueppel like factor-1
GATA 1
Ikaros transcription factor
Helios transcription factor
AML-1

266.22
119.48
39.49
18.76
5.99
5.98
5.06
7.72
24.81
22.52
7.51
6.26
5.18

ferentially expressed in the negative control cells (CD144day 6.5 vs VEGF-R2- day 2.5 and CD144- day 6.5 vs VEGFR2+ day 2.5) were removed from the list. Additional analysis was performed to eliminate remaining false positive
genes (see methods). The final list has several endothelialspecific genes including PECAM-1, claudin 5, and roundabout homolog 4 (Robo 4) (Table 4).
To identify genes that are selectively enriched in endothelial cells during embryonic vascular development, we also
isolated CD144 positive cells from murine embryos at day
9.5. CD144 positive cells were sorted and separated from
CD144 negative cells, and microarray analysis was performed. Because the number of CD144 positive cells isolated from the embryos was much smaller, an
amplification step was performed prior to the microarray
analysis. The results of the microarray analysis also demonstrate an enrichment of several endothelial-specific
genes including ICAM-2, VE-cadherin, PECAM-1, and
endothelial nitric oxide synthase (eNOS) (Table 5). The
expression of several transcription factors was also determined to be enriched in this population of cells, including
SOX 17, the Ets factor Erg and Elk3, Vezf1, Foxo1, and C/
EBP delta. Table 6 shows a condensed list of genes whose
expression is increased in all CD144 positive cells, including the ones isolated at different stages of EB differentiation (day 3.5 and 6.5), and day 9.5 embryos. The genes
upregulated in the CD144 positive cells were not detected

in hematopoietic cells (CD41 positive cells at day 3.5)
(Table 7).
A color map of the relative expression levels obtained via
microarray analysis, including the mesodermal, hematopoietic, early and late endothelial markers was also generated (Figure 5). Signal values were normalized within
the [-3,3] interval as shown by the color scale at the bottom of the image where red indicates high expression and
green indicates low expression.
The expression of a representative number of the genes
identified to be enriched in the CD41 and CD144 expressing stem cells (Table 1,2,3,4,5,6,7) were also evaluated by
quantitative RT-PCR. The results of these studies confirm
the expression patterns observed in each of the populations observed by microarray analysis (Figure 6). For
example, a subset of the genes identified to be enriched in
the CD41 positive cells (day 3.5) compared to VEGF-R2
positive cells (negative for CD41) at day 2.5 (Table 2)
were evaluated by quantitative RT-PCR. These genes,
including Ikaros, AML-1, hemoglobin Y, and CD41, and
are expressed 4–7 fold higher in the CD41 positive cells
(Figure 6A). Similarly a number of genes found to be
upregulated in CD144 positive cells at day 3.5 and 6.5
during ES cell differentiation compared to VEGF-R2 positive cells (negative for CD144) (Table 3 and 4), were similarly validated by quantitative RT-PCR (Figure 6B). Many

Table 3: Comparison of CD144-postive (day 3.5) to VEGF-R2 positive cells (day 2.5)*

Gene Bank Accession number

Gene

Fold Change

BF100813
NM_011587
NM_031198
NM_008452
BB331017
BM220880

Endothelin receptor type B
Tie1
Transcription factor EC
Krueppel like factor 2
Sox11
Forkhead box P1

4.12
5.49
4.02
6.12
5.01
4.87
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Table 4: Comparison of CD144-postive (day 6.5) to VEGF-R2
positive cells (day 2.5)*

Accession Number

Gene

Fold Change

BF100813
D38146
NM_011587
NM_008816
NM_013805
BC020129
AY083458
AI595932
BB331017
NM_008452

Endothelin receptor type B
Ephrin A1
Tie1
PECAM-1
Claudin 5
Robo4
CD 109 antigen
Mef2C
Sox11
KLF2

19.07
5.53
8.82
8.87
10.50
3.55
3.36
5.24
5.36
4.78

of these genes, including the endothelin receptor, Flt-1,
and Tie1, are known to be endothelial cell specific, or
involved in regulating endothelial function. The expression of a similar set of genes was also enriched in CD144
positive versus CD144 negative cells in the mouse embryo
at day E9.5 (Table 5), a subset of which, including Tie1,
Tie2, Ephrin A1, KLF2, and MEF2C, were validated by
quantitative RT-PCR (Figure 6C).
To further define the genes that are upregulated at the
angioblast stage (day 3.5 CD144 positive), and later stages
of endothelial differentiation in the EBs (day 6.5 CD144
positive), and in CD144 positive cells of the embryo (day
9.5), we performed a comparative analysis of these genes

(on-line Additional file 1). We identified 41 genes (section VI) that are enriched in all three populations, 139
genes that are enriched in CD144 positive cells of the EB
at early and later stages (Section IV), and 119 genes (Section V) that are enriched in CD144 positive cells in later
stages of the EB (day 6.5) and in CD144 positive cells of
the embryo at day E9.5. Some of the genes identified in
the overlapping sections of the Venn diagram are listed in
Table 6 and 7. A complete list of the up and down-regulated genes are provided in an on-line supplement [24].
In addition to identifying genes that are enriched at various stages of differentiation, we were also interested in
determining whether the genes identified have previously
been shown to be linked to each other, or to other genes
with regard to specific pathways. In the past few years a
number of bioinformatic programs that are designed to
evaluate potential links between the genes identified and
potential pathways have been developed. We used the
program PathwayAssist (Ariadne Genomics Inc.) to evaluate the potential of underlying existing pathways at various stages of endothelial and hematopoietic
development. In this approach a natural language
processing module, MedScan, is used to describe events of
regulation, interaction and modification between proteins, cell processes and small molecules and the results
are generated in the forms of biological pathways, gene
regulation networks and protein interaction maps [25].
Because considerably more is known regarding the genes
involved in hematopoiesis, we first performed analysis of

Table 5: Comparison of embryonic CD144-postive to CD144-negative cells (day 9.5)*

Accession number

Gene

Fold Change

NM_010494
NM_011587
AW543698
AV319507
NM_007932
NM_010228
BB667216
NM_008816
NM_008713
D43775
D38146
NM_009378
BC020129
AK004781
AV329219
NM_009236
BB831146
AI595932
AK004675
NM_008452
NM_016791
BC005686
AI462296

ICAM-2
Tie1
CD144
Multimerin 2
Endoglin
Flt-1
Von Willebrands Factor
PECAM-1
Endothelial nitric oxide synthase
Endothelin-1
Ephrin A1
Thrombomodulin 1
Robo 4
Sox 17
ERG
Sox 18
C/EBP delta
MEF2C
GATA2
KLF2
NFATc1
ELK3
Forkhead box 01

1614.76
239.47
84.44
67.79
106.71
50.20
56.07
31.40
20.83
22.59
13.80
8.77
7.25
34.96
228.66
20.64
8.96
5.17
4.26
3.24
3.27
5.15
2.67
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A

B

Figure
Heat map
5 of selected genes at different stages of ES cell differentiation and embryogenesis
Heat map of selected genes at different stages of ES cell differentiation and embryogenesis. (A) Expression of
selected mesodermal, hematopoietic, and endothelial genes expressed in VEGF-R2 positive (HB), CD41-positive (HP), and
CD144-positive (AB and ET) murine ES cells. (B) Expression of selected genes identified as being enriched in CD144+ cells in
the developing mouse embryo at day E9.5 compared to CD144-cells. Transcription factors are denoted with a blue color. Signal values are normalized within the [-3,3] interval as shown by the color scale at the bottom of the image where red indicates
high expression and green indicates low expression.
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Figure 6 RT-PCR of selected genes identified by microarray analysis
Quantitative
Quantitative RT-PCR of selected genes identified by microarray analysis. (A) Fold induction, as measured by quantitative RT-PCR, of the expression of representative genes identified as being enriched in CD41 positive cells (day 3.5) compared to VEGF-R2 positive, CD41 negative cells at day 2.5 (Table 1B). (B) Fold induction of representative genes in CD144
positive cells at day 3.5 (gray bars) and day 6.5 (black bars) compared to VEGF-R2 positive, CD144 negative cells at day 2.5
(Table 1C and D). (C) Fold induction of a subset of genes identified in CD144 positive versus CD144 negative cells in the
developing mouse embryo at day E9.5, as measured by quantitative RT-PCR (Table 1E).
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Table 6: Genes Enriched in all CD144-positive cells

Gene

Fold Change (vs. CD144-E9.5)

(d 6.5 vs HB)

304.4
239.5
21.72
13.8
8.7
3.24

8.78
6.82
11.35
7.87
4.56
3.66

CD34
Tie1
Endomucin
Ephrin A1
TFEC
KLF2

the genes enriched in the CD41 positive cells. The initial
analysis was performed using transcription factors identified in the CD41 positive cells at day 3.5 in the differentiating EBs compared to the VEGF-R2 positive cells at day
2.5. When the transcription factors alone are entered into
this pathway analysis, the specific factors are linked in
multiple ways. For example, KLF1 and GATA1, which are
known to be involved in erythropoiesis cluster together
(Additional file 2) with links to references for pathways).
Similarly, Ikaros, Aiolos, and Helios, zinc finger transcription factors, are involved in lymphopoiesis are linked
together. AML1 (Runx1) is known to be upstream of all of
the hematopoietic lineages. The pathway analysis was further expanded to include other proteins that are enriched
in the CD41 positive population, including the hemoglobin genes, myeloperoxidase, c-kit, glycophorin, and
other genes, in addition to the transcription factors identified. Although, significantly more complex, the pathway
analysis similarly supports the linkage of these transcription factors and pathways with specific target genes along
various hematopoietic lineages (on-line Additional file
3). In addition to demonstrating the utility of this kind of
pathway analysis for linking transcription factors with
known gene targets and pathways that have previously
been defined for hematopoiesis, these results also support

(d 3.5 vs HB)
3.0
2.98
4.07
2.99
4.02
3.69

the potential of this approach for identifying similar pathways during the process of endothelial differentiation.
We used a similar approach to try to identify the underlying molecular mechanisms involved at various stages of
endothelial differentiation. We first evaluated the genes
that are upregulated in CD144 positive cells at day 3.5
(angioblast) compared to the hemangioblast. The transcription factors that are highly enriched in this population include KLF2, Sox11 and the forkhead box P1
transcription factor. Some of the potential networks and
pathways were also evaluated using the PathwayAssist
program (Additional files 4 and 5). Similar analyses were
conducted using the Pathway Assist program for genes
identified to be enriched in CD144 positive cells (ES cell
day 6.5) compared to day 2.5 VEGF-R2 positive ES cells
(Additional files 6 and 7) and for CD144 positive cells
isolated from mouse embryos at day 9.5, which is comparable to day 6.5 in the ES cell differentiation system, compared to CD144 negative cells (Additional files 8 and 9).
We recognize that there are limitations of this type of analysis, and that the results of this analysis are only suggestive
of potential pathways among the identified genes and
transcription factors, and these analyses are therefore presented as supplemental data. Future studies will be

Table 7: Genes that showed increased expression in CD144-positive cells from EBs (day 6.5) and in the embryo (day 9.5) compared to
CD41-positive (day 3.5) and CD144-negative cells (day 6.5) from Ebs

Accession number

Gene

NM_010494
AW543698
AV319507
NM_016900
NM_013805
D38146
AY083458
BC020129
NM_007585
NM_008816
AI595932
NM_011441

ICAM-2
CD144
Multmerin 2
Caveolin2
Claudin 5
Ephrin A1
CD109 antigen
Robo 4
Annexin A2
PECAM-1
MEF2C
Sox 17

(EC vs HB)
3.37
3.65
3.83
5.49
3.76
7.87
3.36
3.55
6.0
6.5
6.86
4.14

(EC vs CD144-cells)
1614.76
84.44
67.79
114.87
36.04
13.80
9.83
7.25
7.25
31.40
5.17
34.96

* The values shown in the columns are corrected fold changes (FC). The corrected FC for a transcript is obtained by subtracting the FC for the
particular transcript in the negative control populations from FC for the positive populations (see methods for details).
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needed to verify specific aspects of the putative pathways
identified.

Discussion
Overlap between hematopoietic and endothelial lineages
The close association of endothelial and hematopoietic
lineage has now been demonstrated in several studies in a
wide variety of species including xenopus, mice, and
humans. Our studies similarly support a very close temporal and spatial expression pattern of endothelial and
hematopoietic progenitor cells in differentiating ES cells.
In human embryonic tissues, a population of endotheliallike cells with endothelial and hematopoietic potential
expressing VEGF-R2, VE-cadherin, but not CD45, was
similarly identified [26]. We observed weak VE-cadherin
expression on CD41 positive cells in both the yolk sac and
differentiating EBs, but did not observe CD41 expression
on endothelial cells lining the vascular channels in the EB
or yolk sac, suggesting that as CD41 expression occurs the
cells bud off of the developing vasculature.
Differentiation of the hemangioblast toward the
hematopoietic lineage
Several transcription factors have been shown to be critical for different stages of hematopoietic cell differentiation. Some of the critical transcription factors known to
play a role early in hematopoietic cell differentiation
include Runx-1 (AML-1), GATA-1, and members of the
Ikaros zinc finger transcription factor family. We also
observed enrichment for these factors in early CD41 positive cells within differentiating EBs based on our microarray data. Although the EB is generally considered as a
model of primitive hematopoiesis, similar to what is
observed in the yolk sac, the expression of many Ikaros
family members that are known to regulate several different hematopoietic lineages suggest a possible broader role
for the CD41 positive cells identified in developing EBs in
several hematopoietic lineages [27].
Differentiation of the hemangioblast toward the
endothelial lineage
Considerably less is known about the transcription factors
and molecular mechanisms involved in regulating the differentiation of the hemangioblast along the endothelial
lineage. In early (day 3.5) CD144 positive cells we
observed that the increased expression of genes involved
in regulating endothelial function such as Tie1 and the
endothelin receptor B, compared to genes expressed in
VEGF-R2 positive hemangioblast cells (day 2.5). We similarly identified a select number of transcription factors
that were enriched in these cells, including KLF2, Sox11,
and forkhead box (Fox) P1. Targeted disruption of
FOXP1, which is expressed in the endocardium of the
heart, is associated with abnormalities in cardiac development, similar to that observed with NFATc1 [28]. The

http://www.biomedcentral.com/1471-2164/9/240

Krueppel-like factor (KLF) family members have also been
shown to be involved in cellular differentiation. KLF2 is
expressed in the endothelium and is upregulated in
response to fluid shear stress [29,30].
Because the early CD144 positive cells may not represent
fully differentiated endothelial cells, microarray analysis
was also performed on CD144 positive cells at a later stage
of differentiation in the EBs (day 6.5) and isolated from
the embryo (day 9.5). In addition to increased expression
of several Sox family members (11 and 17), the expression
of several other transcription factors including the nuclear
hormone receptor COUP-TFII (NR2F1), MEF2C, and
KLF2, were observed. Targeted disruption of the orphan
nuclear receptor COUP-TFII results in abnormal vascular
and cardiac development [31]. One of the main downstream targets of COUP-TFII is the angiogenic factor Angiopoietin-1. COUP family members are involved in
regulating the expression of BMP-4 during embryogenesis. BMP-4 promotes hematopoiesis and angiogenesis
during vascular development [32].
In CD144 expressing cells of the embryo (day 9.5) we
observed significant overlap in the endothelial-specific
genes and transcription factors upregulated in the CD144
positive cells derived from the embryo and differentiating
EBs at day 6.5. The transcription factors that were highly
expressed and enriched in these cells included, Sox 7, Sox
17, MEF2C, and KLF2. In addition several other transcription factors were also identified in CD144 positive cells of
the embryo including the ETS transcription factor family
members ERG and ELK3, GATA2, NFATc1, Sox18, Forkhead O1A, and C/EBP delta. The Ets transcription factor
ELK3 is highly expressed at sites of vasculogenesis and
angiogenesis during early mouse development [33]. Furthermore, down-regulation of ELK3 is associated with
marked reductions in VEGF expression. Although ELK3
principally functions as a repressor, Ras activation leads to
a phosphorylated form of ELK3 that is highly active [33].
The Ets factor ERG is also enriched in endothelial cells and
down regulation of ERG in endothelial cells is associated
with reductions in the expression of the endothelial-specific genes [34]. The GATA factors have similarly been
shown to regulate endothelial-specific genes. GATA2 is
involved in the regulation of PECAM-1, endothelin-1, and
ICAM-2 [35-37]. Both the forkhead family members and
NFATc1 function as transcriptional mediators of VEGF in
endothelial cells [38,39]. There are no previous reports
suggesting a role for C/EBP delta in endothelial function
or gene expression.
Microarray chip analysis has been used in a number of
studies for uncovering genes that are differentially
expressed during hematopoietic and endothelial differentiation (see Table 8). In most of these studies, differentiat-
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Table 8: Microarray Studies of Hematopoietic (HP) and Endothelial Cell (EC) Differentiation in EBs

Study

Species

Markers

Differentiation

1. Chen D et al[40]
2. Woll PS et al[41]
3. Schenke K et al[42]
4. Lu SJ et al[43]
5. Wang H et al[44]
6. Williamson AJ et al[45]
7. Rolny C et al[46]
8. Wang C. et al[47]
9. Wu Y. et al[48]
10. Ferguson JE et al[49]
11. Ng YS et al[50]

Human
Human
Human
Human
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse

Whole EBs
CD31, CD34, Flk-1
Whole ES
Whole EB/ES
VEGF-R2
Bry/VEGF-R2
CD31, VEGF-R2
Whole EBs
VEGF-R2
VEGF-R2
Whole EBs

HP
HP/EC
HP/EC
EC
EC
HP
EC
HP/EC
EC
EC
VEGF

ing mouse or human ES cells have been used as a model
system for hematopoietic/endothelial differentiation. Isolation of the VEGF-R2+ cell population at an early stage of
ES cell differentiation was done in all of the mouse ES
cells studies as an already established population with
hemangioblast properties [41-43,45-47]. Human ES cell
hemangioblasts were more tightly defined by sorting out
the VEGFR-2+/CD34+ or VEGFR-2+/CD31+ cells [38]. A
number of mesodermal markers were identified in the
VEGFR-2+ cells at D2.5 of differentiation including Brachyuary [37,40], msh homeo box homolog 1 (Msx1),
NODAL, inhibin BA/BB [37], Hand1, Mesp1 [40], and
canonical Wnt-signalling associated genes such as Wnt3a
and Wnt8a [42]. These genes are involved in processes
such as development, transcription, organ and system
development, with genes such as Sox9, HoxB2, and
HoxB3 being specifically involved in hemangioblast differentiation [40].
During the hemangioblast phase a number of early
hematopoietic and endothelial markers are found to be
co-expressed on the VEGFR-2+ cells from day 3–6 of differentiation. Genes found in these group include CD34,
TAL/SCL, Runx1/AML1, GATA-2/3, Lmo2, Notch1, c-kit,
CD41, HoxB4 (all of them referred to as hematopoietic
commitment markers), and genes thought to be expressed
on both, hematopoietic and endothelial progenitors
including CD31, VE-cadherin, CXCRF, Flt-1 [[37,38] and
[41]], KDR [40], TGFα-1, Bmp7, Smad1, Wnt associated
genes FrzB, β-catenin, N-cadherin, Msx2, Cyclin D1, Dkk1
[41], lysocardiolipin acyltransferase (Lycat) [44] and
finally PRDM6, encoding a Krueppel-like zinc finger protein (KLF) that functions in cell-fate decisions and malignant transformation [45]. Most of these genes are
downregulated as the divergence of the two cell lines takes
place, however, a number of these markers maintain
steady levels of expression throughout the course of differentiation. The onset of the definitive hematopoiesis is
marked by the expression of CD45, the genes involved in
adult hematopoietic cell renewal (PIK3R1, MDR1, IRS1,
RGS18, SUMO-1 and Wnt5) [37], CXCL12, Alcam [39],

Modulators

Col IV, FGF4
VEGF, BMP4
Wnt

Lycat
PRDM6
ASB4

mayeloblastosis oncogene (Myb) and Hemoglobin genes
[43].
Genes whose expression is enriched in more mature
endothelial cells from day 6 and onwards include VE-cadherin, CXCR4 [38], Angiopoietin 2 (Ang2), Endothelin 1
(End1) [39], ICAM-2, neuropilin-1, endoglin, transforming growth factor genes (TGFβ-2, BMP4 and BMPR-1),
Wnt associated genes (Wnt2, Wnt5a, Nkd1, cyclin D2,
Frzd7, Lef1, Frzb, Sox17, Msx2, fibrinogen, Myc) [41], Tie2, genes involved in angiogenic response to VEGF such as
PDGFBB, PDGFR-1, Shb [43], ASB4 (which functions in
vascular differentiation in an oxygen-dependent manner)
[46], caveolin, Hey1, FGFR-1, and adhesion protein genes
cadherin 5 and claudin 3 [47]. The findings from our
microarray studies are in accord with the previously published studies. In addition, we have identified several
additional genes such as Ikaros and Helios zinc-finger
transcription factors, Erg, claudin 5, and Sox17, that segregate with the hematopoietic or endothelial cell populations (see Table 1,2,3,4,5,6,7). Future studies will be
needed to identify whether or not these genes play a significant role as determinants of endothelial or hematopoietic cell differentiation.

Conclusion
In conclusion, the results of our study support the use of
embryonic stem cells to study the molecular events underlying hematopoiesis and endothelial differentiation. Our
results demonstrate the expression of distinct sets of genes
in populations of embryonic stem cells expressing CD41
or CD144 that are consistent with genes associated with
the hematopoietic or endothelial lineages. Future studies
should be directed at defining the role of selected transcription factors that are enriched in selected subsets of
stem cells during the process of differentiation.
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